Literature DB >> 23443752

When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines.

K C Reber1, S Piening, J E Wieringa, S M J M Straus, J M Raine, P A de Graeff, F M Haaijer-Ruskamp, P G M Mol.   

Abstract

Serious safety issues relating to drugs are communicated to health-care professionals via Direct Health-Care Professional Communications (DHPCs). We explored which characteristics determined the impact of DHPCs issued in the Netherlands for ambulatory-care drugs (2001-2008). With multiple linear regression, we examined the impact on the relative change in new drug use post-DHPC of the following: time to DHPC, trend in use, degree of innovation, specialist drug, first/repeated DHPC, DHPC template, and type of safety issue. DHPCs have less impact on use of specialist drugs than nonspecialist drugs (P < 0.05). The DHPCs' impact increased after availability of a template emphasizing the main problem (P < 0.05), and for safety issues with a risk of death and/or disability (both P < 0.05) (adjusted R² = 0.392). Risk communication can be effective, specifically in case of well-structured information, and very serious safety issues. Effectiveness may improve by tailoring DHPCs and adding other communication channels, for example for drugs that are increasingly being used.

Entities:  

Mesh:

Year:  2012        PMID: 23443752     DOI: 10.1038/clpt.2012.262

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

Review 1.  Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.

Authors:  Anjan Kumar Banerjee; Inge M Zomerdijk; Stella Wooder; Simon Ingate; Stephen J Mayall
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

2.  The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands.

Authors:  Sigrid Piening; Pieter A de Graeff; Sabine M J M Straus; Flora M Haaijer-Ruskamp; Peter G M Mol
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

3.  Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings.

Authors:  Adeline Gallini; Sandrine Andrieu; Julie M Donohue; Naïma Oumouhou; Maryse Lapeyre-Mestre; Virginie Gardette
Journal:  Eur Neuropsychopharmacol       Date:  2013-09-17       Impact factor: 4.600

4.  Decrease in Switches to 'Unsafe' Proton Pump Inhibitors After Communications About Interactions with Clopidogrel.

Authors:  Willemien J Kruik-Kollöffel; Job van der Palen; Myrthe P P van Herk-Sukel; H Joost Kruik; Kris L L Movig
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

5.  Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.

Authors:  Mateo de Bardeci; Waldemar Greil; Renate Grohmann; Johanna Seifert; Hans Stassen; Jamila Willms; Ursula Köberle; René Bridler; Gregor Hasler; Siegfried Kasper; Eckart Rüther; Stefan Bleich; Sermin Toto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-02-25       Impact factor: 5.270

6.  Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interaction.

Authors:  Willemien J Kruik-Kollöffel; Job van der Palen; H Joost Kruik; Myrthe P P van Herk-Sukel; Kris L L Movig
Journal:  Pharmacol Res Perspect       Date:  2016-07-18

7.  The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.

Authors:  Kanika Anand; Ingrid Sketris; Ying Zhang; Adrian Levy; John-Michael Gamble
Journal:  Drugs Real World Outcomes       Date:  2017-12

8.  Antipsychotic prescribing for Alzheimer's disease and related disorders in specialized settings from 2010 to 2014 in France: a repeated cross-sectional study.

Authors:  Karim Tifratene; Valeria Manera; Roxane Fabre; Auriane Gros; Susanne Thummler; Christian Pradier; Philippe Robert; Renaud David
Journal:  Alzheimers Res Ther       Date:  2017-04-26       Impact factor: 6.982

9.  Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands.

Authors:  Esther de Vries; Petra Denig; Sieta T de Vries; Taco B M Monster; Jacqueline G Hugtenburg; Peter G M Mol
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

10.  Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron.

Authors:  Frank Moriarty; Shegufta Razzaque; Ronald McDowell; Tom Fahey
Journal:  J Clin Med       Date:  2018-10-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.